(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
To fix a patient's irregular heartbeat, doctors first tested its digital 'twin' - 210 Setting up camp Shelters That Offer Both Excellence and Isolation
- 3Vote in favor of the subject that you see as generally captivating and intelligent!
- 4Novo Nordisk slashes prices of popular weight loss and diabetes drugs
- 5Keep It Cool: Uncovering Famous Fridge Brands for Each Home
- Craig the beer-ambassador elephant dies aged 54
- Israel reports first missile fire from Yemen since start of Iran war
- Figure out How to Recognize the Right Areas for 5G Pinnacles\
- 7 Fun Plans to Make Film Evenings Seriously Invigorating (You'll Cherish #5!)
- UN experts urge investigation into Israel’s killing of Lebanese journalists
- Key Training: Picking a Significant for Monetary Achievement
- Canada's Friendly Sunshine Coast City Is An Outdoor Playground Perfect For Hiking And Paddling
- Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- Spain’s Picos de Europa: What to see and do in ‘the world’s most beautiful place’
